Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Filing 480

STATEMENT of facts re #478 MOTION for Summary Judgment of Non-Infringement of Claim 1 of Patent No. 5,955,422 and Claims 9 and 12 of Patent No. 5,547,933 (Pursuant to Local Rule 56.1). (Rizzo, Nicole)

Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Doc. 480

Case 1:05-cv-12237-WGY

Document 480

Filed 06/11/2007

Page 1 of 4

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -) ) AMGEN INC. ) Plaintiff, ) ) v. ) Civil Action No. ) 05 CV 12237 WGY F. HOFFMANN-LA ROCHE LTD., ROCHE ) DIAGNOSTICS GMBH, and HOFFMAN-LA ROCHE ) INC. ) ) Defendants. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -) RULE 56.1 STATEMENT OF UNDISPUTED MATERIAL FACTS IN SUPPORT OF DEFENDANTS' MOTION FOR SUMMARY JUDGMENT OF NON-INFRINGEMENT OF CLAIM 1 OF PATENT NO. 5,955,422 AND CLAIMS 9 AND 12 OF PATENT NO. 5,547,933 Defendants F. Hoffmann-La Roche Ltd, Roche Diagnostics GmbH and Hoffmann-La Roche Inc. (collectively "Roche") submit the following statement of undisputed material facts, pursuant to Local Rule 56.1, in support of their motion for summary judgment of non-infringement of Claim 1 Patent No. 5,955,422 (the `422 patent) and claims 9 and 12 of Patent No. 5,547,933 (the `933 patent). 1. In this action, plaintiff Amgen Inc. alleges that Roche infringes claim 1 of the `422

patent and claims 9 and 12 of the `933 patent. (Suh Decl,1 Ex. D at p. 3). 2. Claim 1 of the `422 patent and claims 9 and 12 of the `933 patent all contain the

limitation "a pharmaceutical composition comprising . . . a pharmaceutically acceptable diluent, adjuvant or carrier." (Id. Ex. A, claim 1; Ex. B, claims 9 and 12).
1

"Suh Decl." refers to the Declaration of Howard S. Suh in Support of Defendants' Motion for Summary Judgment of Non-Infringement of Claim 1 of Patent No. 5,955,422 and Claims 9 and 12 of Patent No. 5,547,933.

Dockets.Justia.com

Case 1:05-cv-12237-WGY

Document 480

Filed 06/11/2007

Page 2 of 4

3.

On April 17, 2007, this Court construed the phrase "a pharmaceutical composition

comprising . . . a pharmaceutically acceptable diluent, adjuvant or carrier" common to claim 1 of the `422 patent and claims 9 and 12 of the `933 patent to mean " a composition suitable for administration to humans containing a diluent, adjuvant or carrier." (Id. Ex. C at 77:1-3). 4. Amgen's expert, Dr. Lodish, admits that during the formulation process Roche adds "a

diluent and carrier" to the active ingredient CERA. (See id. Ex. F ¶ 92). 5. The common specification of the `422 and `933 patents states that ""[a]lso comprehended

by the invention are pharmaceutical compositions comprising effective amounts of polypeptide products of the invention together with suitable diluents, adjuvants and/or carriers. . . ." (Id. Ex. A at col. 12, ln. 5-8; Ex. B at col 12, ln. 1-4). 6. During an interference with U.S. Patent No. 4,806,524, applicant Lin's counsel suggested

the count: "An erythropoietin preparation containing one or more selected from the group consisting of bovine serum albumin, human serum albumin and gelatin." (Id. Ex. J at 4; see also Ex. K; Ex. L).

2

Case 1:05-cv-12237-WGY

Document 480

Filed 06/11/2007

Page 3 of 4

DATED:

Boston, Massachusetts June 11, 2007

Respectfully submitted, F. HOFFMANN-LA ROCHE LTD, ROCHE DIAGNOSTICS GMBH, and HOFFMANN-LA ROCHE INC. By their Attorneys, /s/ Nicole A. Rizzo Lee Carl Bromberg (BBO# 058480) Julia Huston (BBO# 562160) Keith E. Toms (BBO# 663369) Nicole A. Rizzo (BBO # 663853) BROMBERG & SUNSTEIN LLP 125 Summer Street Boston, MA 02110 Tel: [phone] [e-mail] Leora Ben-Ami (pro hac vice) Mark S. Popofsky (pro hac vice) Patricia A. Carson (pro hac vice) Thomas F. Fleming (pro hac vice) Howard S. Suh (pro hac vice) Peter Fratangelo (BBO# 639775) KAYE SCHOLER LLP 425 Park Avenue New York, NY 10022 Tel: [phone]

3

Case 1:05-cv-12237-WGY

Document 480

Filed 06/11/2007

Page 4 of 4

CERTIFICATE OF SERVICE I hereby certify that this document filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non registered participants on the above date. /s/ Nicole A. Rizzo Nicole A. Rizzo
03099/00501 684827.1

4